2024
A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program
Kember R, Rentsch C, Lynch J, Vujkovic M, Voight B, Justice A, Program M, Assimes T, Kranzler H. A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program. Alcohol Clinical And Experimental Research 2024 PMID: 39580711, DOI: 10.1111/acer.15445.Peer-Reviewed Original ResearchCoronary heart diseaseMR analysisMillion Veteran ProgramGenetic scoreAlcohol consumptionBody mass indexMendelian randomizationCardiometabolic diseasesVeteran ProgramAfrican AmericansAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) scoresEuropean AmericansHispanic AmericansAssociation of alcohol consumptionMultivariable MR analysisAssociated with CHD riskMendelian randomization studiesRisk of cardiometabolic diseasesAssociated with alcohol consumptionCardiometabolic disease riskIncidence of coronary heart diseaseObservational studyNested case-control studyReduced risk of cardiometabolic diseasesMulti-ancestry population
2023
Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
Vickers-Smith R, Justice A, Becker W, Rentsch C, Curtis B, Fernander A, Hartwell E, Ighodaro E, Kember R, Tate J, Kranzler H. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans. American Journal Of Psychiatry 2023, 180: 426-436. PMID: 37132202, PMCID: PMC10238581, DOI: 10.1176/appi.ajp.21111097.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol consumptionAUD diagnosisHispanic veteransWhite veteransUse disordersPrevalence of AUDAlcohol Use Disorders Identification TestUnhealthy alcohol useICD-10 codesAUDIT-C scoresSelf-reported alcohol consumptionAlcohol-related disordersDiagnosis of AUDDisorders Identification TestMaximum scoreSelf-reported raceElectronic health recordsPrimary outcomeAlcohol consumption levelsPotential confoundersHigh prevalenceMillion Veteran ProgramGreater oddsICD-9Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans
Naps M, Leong S, Hartwell E, Rentsch C, Kranzler H. Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans. Alcohol Clinical And Experimental Research 2023, 47: 438-447. PMID: 36810985, DOI: 10.1111/acer.15011.Peer-Reviewed Original ResearchConceptsSerum bicarbonate concentrationAlcohol use disorderMetabolic acidosisMEq/LAlcohol consumptionTopiramate therapyAlcohol Use Disorders Identification Test-Consumption scoresVeterans Health Administration electronic health record dataBicarbonate concentrationPropensity score-matched control groupPropensity score-matched controlsMean daily dosageSignificant metabolic acidosisElectronic health record dataDiagnosis of AUDHealth record dataBaseline alcohol consumptionDifferences linear regression modelThree-level measureAcid-base balanceTopiramate dosageTopiramate prescriptionsMean followTopiramate treatmentDaily dosage
2022
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelAssociation of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data
Kranzler HR, Leong SH, Naps M, Hartwell EE, Fiellin DA, Rentsch CT. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. Addiction 2022, 117: 2826-2836. PMID: 35768956, PMCID: PMC10317468, DOI: 10.1111/add.15980.Peer-Reviewed Original ResearchConceptsAUDIT-C scoresAlcohol use disorderElectronic health record dataHealth record dataUse disordersNEG patientsTopiramate dosageAlcohol Use Disorders Identification Test-Consumption scoresPropensity score-matched groupsHistory of AUDParallel group comparisonPropensity score-matched comparison groupRecord dataBaseline drinking levelsReduced alcohol consumptionHealth care systemTopiramate prescriptionsPre-post differencesAUD historyTopiramate's effectsPatientsRecord diagnosisAlcohol consumptionTopiramateComparison group
2019
Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days